Want to see TSE:KPT full AI Analyst Report?
Top Page
KP Tissue
(TSX:KPT)
Select Model
Select Model
Rating:52Neutral
Price Target:
C$11.50
▼(-10.16% Downside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by weak technical momentum (below key moving averages with deeply depressed RSI/Stoch) and reduced financial-data confidence due to missing/zero-reported revenue/margin and recent cash flow figures. Offsetting these are a healthier profitability narrative in the financial statements, supportive valuation (moderate P/E and high dividend yield), and a generally positive earnings-call tone with steady near-term EBITDA guidance despite noted cost and market-share risks.
Positive Factors
EBITDA Growth and Margin Expansion
Strong EBITDA growth alongside nearly three percentage points of margin expansion indicates improved operating performance and pricing or productivity benefits. If sustained, this strengthens cash-generation capacity and provides more resources for reinvestment, debt management, and competitive initiatives.
Negative Factors
Canadian Consumer Share Erosion
The Canadian consumer business is facing both weaker revenue and category share losses, showing that private-label trade-down is affecting market position rather than only short-term demand. Persistent erosion could pressure volumes, brand investment returns, and the durability of consumer margins.
Read all positive and negative factors
Positive Factors
Negative Factors
EBITDA Growth and Margin Expansion
Strong EBITDA growth alongside nearly three percentage points of margin expansion indicates improved operating performance and pricing or productivity benefits. If sustained, this strengthens cash-generation capacity and provides more resources for reinvestment, debt management, and competitive initiatives.
Read all positive factors
KP Tissue (KPT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$117.23M
Dividend Yield6.68%
Average Volume (3M)19.71K
Price to Earnings (P/E)13.1
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth98.42%
CountryCA
Employees2,700
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.89
Shares Outstanding10,032,387
10 Day Avg. Volume16,511
30 Day Avg. Volume19,711
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.47
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$13.50Price Target Upside5.47% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)1.19
Revenue Forecast (FY)C$2.25B
KP Tissue Business Overview & Revenue Model
Company Description
KP Tissue Inc. conducts its core operations through its investment in Kruger Products L.P., focusing on the creation, dissemination, and sale of a diverse range of disposable tissue products throughout Canada and the United States. The company div...
How the Company Makes Money
KPT makes money primarily through its ownership interest in Kruger Products Inc. and receives cash distributions/dividends (when declared) from Kruger Products, which are funded by Kruger Products’ operating cash flows. Kruger Products generates r...
KP Tissue Earnings Call Summary
Earnings Call Date:Aug 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and financial picture: strong adjusted EBITDA growth (+25% YoY), margin expansion, solid U.S. revenue growth (+9.5% YoY), and successful operational improvements (Memphis ramp, production outperformance, product innovation). Offsetting risks include softness and share erosion in the Canadian consumer market, AFH margin pressure from transportation costs, a sequential cash decline driven by working capital, pulp price volatility (notably BEK increases), and uncertainty around the timing and site finalization for the proposed U.S. TAD plant. Management has mitigation plans (share recovery actions, AFH price increases, contingency work on tariffs) and expects Q3 EBITDA to be roughly in line with Q2, but near‑term risks and input‑cost inflation remain focal points.Positive Updates
Strong Adjusted EBITDA Growth
Adjusted EBITDA of $90.6 million in Q2 2026, up 25% year‑over‑year. Adjusted EBITDA margin improved to 16.4% from 13.5% a year ago (≈+2.9 percentage points). Sequentially adjusted EBITDA rose 4.2% (+$3.7 million).
Negative Updates
Soft Canadian Consumer Market and Share Erosion
Canadian revenue declined 2.6% YoY (≈–$7.7 million) and the company experienced share losses in bathroom tissue and paper towel categories as some consumers traded down to private label; management noted high prior‑year comps (Made in Canada activity) and expects a share recovery plan to drive improvement in H2 2026.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Adjusted EBITDA Growth
Adjusted EBITDA of $90.6 million in Q2 2026, up 25% year‑over‑year. Adjusted EBITDA margin improved to 16.4% from 13.5% a year ago (≈+2.9 percentage points). Sequentially adjusted EBITDA rose 4.2% (+$3.7 million).
Read all positive updates
Company Guidance
Management's guidance calls for third-quarter adjusted EBITDA to be "in the range of" Q2 2026 results — i.e., roughly the Q2 adjusted EBITDA of $90.6 million (Q2 margin 16.4%) — and no material tariff impact is expected (tariff exposure estimated at <1% of total sales); 2026 capital expenditures are guided to $90–$110 million (Q2 CapEx $15.5M; Q1 $16M). Other relevant Q2 metrics cited that frame the outlook: revenue $550.9M (+2.8% YoY; +$6.3M or +1.1% sequential), Canada revenue down $7.7M (-2.6% YoY) while U.S. revenue up $22.5M (+9.5% YoY), consumer revenue $457.6M (+1.9% YoY) and Away‑From‑Home revenue $93.3M (+7.4% YoY); adjusted EBITDA up $18.1M (+25% YoY), consumer adj. EBITDA $85.3M (margin 18.6%, +300 bps YoY; +$1.4M sequential), AFH adj. EBITDA $8.5M (margin 9.1%, -100 bps YoY; +$2.2M sequential), net income $22.1M, cash $165.2M (down from $205.9M), leverage 2.9x, pulp trends NBSK -13.4% YoY and BEK +15.2% YoY, and an AFH price increase of 3–5% effective Sept. 1 (affecting about two‑thirds of that business).KP Tissue Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
62
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 171.42M | 318.23M | 264.78M | 239.64M | 116.74M | 153.75M |
| Net Income | 8.94M | 8.50M | 2.43M | -4.94M | -10.25M | 1.24M |
Balance Sheet | ||||||
| Total Assets | 72.88M | 71.60M | 71.31M | 70.61M | 81.71M | 80.72M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.80M | 1.80M | 1.80M | 2.25M | 7.68M | 4.85M |
| Stockholders Equity | 71.08M | 69.80M | 69.52M | 68.36M | 74.03M | 75.87M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | 6.97M | 6.98M | 6.62M | 1.15M |
| Operating Cash Flow | 0.00 | 0.00 | 6.97M | 6.98M | 6.62M | 1.15M |
| Investing Cash Flow | 6.95M | 6.96M | 6.97M | 6.98M | 6.62M | 5.56M |
| Financing Cash Flow | -6.95M | -6.96M | -6.97M | -6.98M | -6.62M | -5.56M |
KP Tissue Technical Analysis
Negative
12.80
Price Trends
12.20
Negative
12.48
Negative
11.56
Positive
Market Momentum
-0.13
Negative
44.05
Neutral
32.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KPT, the sentiment is Negative. The current price of 12.8 is above the 20-day moving average (MA) of 11.72, above the 50-day MA of 12.20, and above the 200-day MA of 11.56, indicating a neutral trend. The MACD of -0.13 indicates Negative momentum. The RSI at 44.05 is Neutral, neither overbought nor oversold. The STOCH value of 32.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KPT.
KP Tissue Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | C$438.21M | 13.05 | 17.72% | 6.25% | 10.09% | 21.92% | |
68 Neutral | C$438.21M | 13.05 | 17.72% | 6.23% | 10.09% | 21.92% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | C$749.97M | 21.78 | 6.30% | 2.61% | 14.25% | -44.39% | |
58 Neutral | C$848.39M | 13.10 | 14.14% | 5.45% | -5.74% | -3.64% | |
52 Neutral | C$117.23M | 13.13 | 12.81% | 6.68% | ― | 98.42% |
* Consumer Defensive Sector Average
TSE:KPT
KP Tissue
11.69
2.95
33.77%
TSE:CSW.A
Corby Spirit&Wine A
15.40
2.37
18.16%
TSE:CSW.B
Corby Spirit&Wn B NV
15.35
2.61
20.45%
TSE:HLF
High Liner Foods
26.78
10.69
66.43%
TSE:RSI
Rogers Sugar
6.60
0.74
12.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.